Rapamycin Improves the Response of Effector and Me... - BV FAPESP
Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Rapamycin Improves the Response of Effector and Memory CD8(+) T Cells Induced by Immunization With ASP2 of Trypanosoma cruzi

Full text
Author(s):
Show less -
Moraschi, Barbara Ferri [1, 2] ; Noronha, Isau Henrique [1, 2] ; Ferreira, Camila Pontes [1, 2] ; Cariste, Leonardo M. [3] ; Monteiro, Caroline B. [3] ; Denapoli, Priscila [2] ; Vrechi, Talita [4] ; Pereira, Gustavo J. S. [4] ; Gazzinelli, Ricardo T. [5, 6] ; Lannes-Vieira, Joseli [7] ; Rodrigues, Mauricio M. [1, 2] ; Bortoluci, Karina R. [4, 2] ; Vasconcelos, Jose Ronnie C. [1, 2, 3]
Total Authors: 13
Affiliation:
[1] Fed Univ Sao Paulo UNIFESP, Dept Microbiol Immunol & Parasitol, Sao Paulo - Brazil
[2] Fed Univ Sao Paulo UNIFESP, Ctr Mol & Cellular Therapy, Mol Immunol Lab, Sao Paulo - Brazil
[3] Univ Fed Sao Paulo, Recombinant Vaccines Lab, Dept Biosci, Santos, SP - Brazil
[4] Fed Univ Sao Paulo UNIFESP, Dept Pharmacol, Sao Paulo - Brazil
[5] Fiocruz MS, Rene Rachou Res Ctr, Belo Horizonte, MG - Brazil
[6] Univ Massachusetts, Med Sch, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 - USA
[7] Fiocruz MS, Oswaldo Cruz Inst, Laboratoy Biol Interact, Rio De Janeiro - Brazil
Total Affiliations: 7
Document type: Journal article
Source: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY; v. 11, MAY 25 2021.
Web of Science Citations: 1
Abstract

Deficiency in memory formation and increased immunosenescence are pivotal features of Trypanosoma cruzi infection proposed to play a role in parasite persistence and disease development. The vaccination protocol that consists in a prime with plasmid DNA followed by the boost with a deficient recombinant human adenovirus type 5, both carrying the ASP2 gene of T. cruzi, is a powerful strategy to elicit effector memory CD8(+) T-cells against this parasite. In virus infections, the inhibition of mTOR, a kinase involved in several biological processes, improves the response of memory CD8(+) T-cells. Therefore, our aim was to assess the role of rapamycin, the pharmacological inhibitor of mTOR, in CD8(+) T response against T. cruzi induced by heterologous prime-boost vaccine. For this purpose, C57BL/6 or A/Sn mice were immunized and daily treated with rapamycin for 34 days. CD8(+) T-cells response was evaluated by immunophenotyping, intracellular staining, ELISpot assay and in vivo cytotoxicity. In comparison with vehicle-injection, rapamycin administration during immunization enhanced the frequency of ASP2-specific CD8(+) T-cells and the percentage of the polyfunctional population, which degranulated (CD107a(+)) and secreted both interferon gamma (IFN gamma) and tumor necrosis factor (TNF). The beneficial effects were long-lasting and could be detected 95 days after priming. Moreover, the effects were detected in mice immunized with ten-fold lower doses of plasmid/adenovirus. Additionally, the highly susceptible to T. cruzi infection A/Sn mice, when immunized with low vaccine doses, treated with rapamycin, and challenged with trypomastigote forms of the Y strain showed a survival rate of 100%, compared with 42% in vehicle-injected group. Trying to shed light on the biological mechanisms involved in these beneficial effects on CD8(+) T-cells by mTOR inhibition after immunization, we showed that in vivo proliferation was higher after rapamycin treatment compared with vehicle-injected group. Taken together, our data provide a new approach to vaccine development against intracellular parasites, placing the mTOR inhibitor rapamycin as an adjuvant to improve effective CD8(+) T-cell response. (AU)

FAPESP's process: 18/15607-1 - Role of specific CD4+ and CD8+ T cells generated by different vaccination protocols against experimental Trypanosoma cruzi infection
Grantee:Jose Ronnie Carvalho de Vasconcelos
Support Opportunities: Research Grants - Young Investigators Grants - Phase 2
FAPESP's process: 16/02840-4 - Role of pharmacological inhibitor mTOR rapamycin in response of memory CD8+ T cells induced by heterologous prime-boost immunization
Grantee:Barbara Ferri Moraschi
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 15/08814-2 - Role of integrin receptors and chemokines in the migration of specific CD8+ T cells generated by genetic immunization with ASP -2 Trypanosoma cruzi
Grantee:Camila Pontes Ferreira
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 14/19422-5 - Pharmacological effect of the mTOR inhibitor rapamycin in response to memory CD8+ t lymphocytes induced by genetic immunization using heterologous prime-boost
Grantee:Barbara Ferri Moraschi
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 12/22514-3 - Migration study of specific T cells generated by vaccination or Trypanosoma cruzi infection
Grantee:Jose Ronnie Carvalho de Vasconcelos
Support Opportunities: Research Grants - Young Investigators Grants